CD274 and prostate cancer: In contrast to the resistant TRAMP-C2 prostate cancer model, either Rab27a knockout or anti-PD-L1 antibody blockade exhibited less of an effect on the MC38 colorectal cancer growth compared with PD-L1 genetic deletion (Poggio et al., 2019).